title: Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors.
abstract: This study aimed to assess the diagnostic value of vimentin expression in differentiating endometrioid adenocarcinoma of primary uterine corpus and ovarian origin. Immunohistochemical analyses for the expression of vimentin in tumoral epithelial cells were performed on 149 endometrioid adenocarcinomas wherein the primary sites were not in question, including whole tissue sections of 27 carcinomas of uterine corpus origin (and no synchronous ovarian tumor), 7 carcinomas of ovarian origin (and no synchronous uterine corpus tumor) and a tissue microarray (TMA) containing 91 primary uterine corpus and 24 primary ovarian carcinomas. We also assessed 15 cases that synchronously involved the uterine corpus and ovary, 15 cases of metastasis to organs/tissues other than uterine corpus or ovary as well as 7 lymph node metastases. Vimentin was negative in 97% (30/31) of primary ovarian carcinomas. In contrast, 82% (97/118) of primary uterine corpus carcinomas were vimentin-positive. Vimentin expression was discordant in 53% of synchronous tumors. The sensitivity and specificity of negative vimentin staining in predicting an ovarian primary were 97% and 82%, respectively, whereas parallel values for positive vimentin staining in predicting a primary uterine tumor were 82% and 97%, respectively. The pattern of vimentin expression in all cases was maintained in their respective regional lymph nodes and distant metastases. In conclusion, ovarian and uterine corpus endometrioid adenocarcinomas have different patterns of vimentin expression. If validated in larger and/or different data sets, these findings may have diagnostic value in distinguishing metastatic lesions from double primary tumors involving both sites.
authors.affiliation: Departments of Pathology, Microbiology and Immunology (M.M.D., S.J.K., O.H., O.F.) Obstetrics and Gynecology (D.K., M.A.C., O.F.), Division of Gynecologic Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: Desouki
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Kallas
authors.forename: Dineo
authors.initials: D
authors.lastname: Khabele
authors.forename: Marta A
authors.initials: MA
authors.lastname: Crispens
authors.forename: Omar
authors.initials: O
authors.lastname: Hameed
authors.forename: Oluwole
authors.initials: O
authors.lastname: Fadare
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018269:Carcinoma, Endometrioid / Q000378:metabolism / Q000473:pathology*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D014594:Uterine Neoplasms / Q000473:pathology*; D014746:Vimentin / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D014746:Vimentin